Reverb Therapeutics key facts
- Developer of a cytokine therapy designed for cancer treatment and promoting targeted immune activation while limiting toxicity.
- It has raised $12.5M; the latest was Seed Round ($12.0M) in Feb 2025.
- Notable investors include Life Sciences BC, InBC Investment, Finchley Healthcare Ventures, Amplitude Ventures, InBC Investment Corp. (InBC) — 8 tracked in total.
- Status: Privately Held (backing).
- ·Watch Reverb Therapeutics: the Monday email on marks, rounds and moves
Reverb Therapeutics funding rounds
No funding rounds for Reverb Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Reverb Therapeutics investors
8 investors are on record for Reverb Therapeutics, including Life Sciences BC, InBC Investment, Finchley Healthcare Ventures and Amplitude Ventures.
About Reverb Therapeutics
Developer of a cytokine therapy designed for cancer treatment and promoting targeted immune activation while limiting toxicity. The company uses bispecific antibodies to localize endogenous cytokines to immune cells in the tumor microenvironment (TME) and overcome toxicity issues of exogenously delivered cytokines, enabling cancer patients and the healthcare sector to redirect endogenous cytokines already in the body to cells of interest and treat cancer.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2023
- Employees
- 10
- Website
- reverbtx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Reverb Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.